Login
$PG
$173.02 After hours

$PG 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Other Events

We are acting as counsel to the underwriters in connection with the Registration Statement on Form

02 Nov 2026 8-K: Other Events

We are acting as counsel to the underwriters in connection with the Registration Statement on Form

30 Oct 2026 8-K: Other Events

We are acting as counsel to the underwriters in connection with the Registration Statement on Form

22 Oct 2026 8-K: Regulation FD Disclosure

INTEGRATED GROWTH STRATEGY SUPERIORITY TO WIN WITH CONSUMERS PORTFOLIO PERFORMANCE DRIVES BRAND CHOICE ACROSS OUR BUSINESS CONSTRUCTIVE DISRUPTION PRODUCTIVITY TO FUEL INVESTMENTS ORGANIZATION EMPOWERED • AGILE ACCOUNTABLE

22 Oct 2026 8-K: Results of Operations and Financial Condition

UPDATES NET SALES GUIDANCE FOR THORNE ACQUISITIONMAINTAINS FISCAL YEAR ORGANIC SALES, EPS GROWTH AND CASH RETURN GUIDANCE

16 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On October 13, 2026, the Company held its 2026 Annual Meeting of Shareholders. Set forth below are the final voting results for each of the proposals submitted to a vote of the shareholders.

13 Oct 2026 8-K: Regulation FD Disclosure

P&G Shareholders Also Elect All 12 P&G Director Nominees at 2026 Annual Meeting

29 Jul 2026 8-K: Regulation FD Disclosure

INTEGRATED GROWTH STRATEGY SUPERIORITY TO WIN WITH CONSUMERS PORTFOLIO PERFORMANCE DRIVES BRAND CHOICE ACROSS OUR BUSINESS CONSTRUCTIVE DISRUPTION PRODUCTIVITY TO FUEL INVESTMENTS ORGANIZATION EMPOWERED • AGILE ACCOUNTABLE

29 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CINCINNATI, July 29, 2026 - The Procter & Gamble Company (NYSE:PG) today announced that Shailesh Jejurikar has been appointed Chairman of the Board, effective August 1, 2026. Jejurikar assumes the position in addition to his role as Pres...

29 Jul 2026 8-K: Results of Operations and Financial Condition

Q4 ’26: Net Sales +2%; Organic Sales 0%; Diluted EPS -15%; Core EPS -3%

14 Jul 2026 8-K: Regulation FD Disclosure

CINCINNATI, July 14, 2026 – The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0885 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock...

24 Apr 2026 8-K: Regulation FD Disclosure

INTEGRATED GROWTH STRATEGY SUPERIORITY TO WIN WITH CONSUMERS PORTFOLIO PERFORMANCE DRIVES BRAND CHOICE ACROSS OUR BUSINESS CONSTRUCTIVE DISRUPTION PRODUCTIVITY TO FUEL INVESTMENTS ORGANIZATION EMPOWERED • AGILE ACCOUNTABLE

24 Apr 2026 8-K: Results of Operations and Financial Condition

CINCINNATI, April 24, 2026 - The Procter & Gamble Company (NYSE:PG) reported third quarter fiscal year 2026 net sales of $21.2 billion, an increase of seven percent versus the prior year. Organic sales, which excludes the impacts of fore...

14 Apr 2026 8-K: Regulation FD Disclosure

CINCINNATI, April 14, 2026 – The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared an increased quarterly dividend of $1.0885 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Pre...

22 Jan 2026 8-K: Regulation FD Disclosure

Second quarter results heavily impacted by base period dynamics and underlying market trends. Organic sales were in-line with prior year. Pricing +1% offset by volume -1%. 7 of 10 product categories grew or held organic sales for the qua...

22 Jan 2026 8-K: Results of Operations and Financial Condition

CINCINNATI, January 22, 2026 - The Procter & Gamble Company (NYSE:PG) reported second quarter fiscal year 2026 net sales of $22.2 billion, an increase of one percent versus the prior year. Organic sales, which excludes the impacts of for...

13 Jan 2026 8-K: Regulation FD Disclosure

CINCINNATI, January 13, 2026 – The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred St...

15 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 9, 2025, Jennifer Davis, currently Chief Executive Officer - Health Care, notified the Company of her intent to retire effective June 30, 2026, after more than 33 years of service.

04 Nov 2025 8-K: Other Events

We are acting as counsel to the underwriters in connection with the Registration Statement on Form S-3 (File No. 333-275071) (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Securities Act”), with respec...

03 Nov 2025 8-K: Other Events

We are acting as counsel to the underwriters in connection with the Registration Statement on Form S-3 (File No. 333-275071) (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Securities Act”), with respec...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support